Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
chronic phase chronic myeloid leukemia
treatment-free remission
tyrosine kinase inhibitors
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
20
07
2023
received:
16
07
2023
accepted:
22
07
2023
medline:
12
9
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
The role of IFNα in chronic myeloid leukaemia patients who have achieved a deep molecular response (DMR) is still unknown. The study reported by Irani et al., which shows the prospective biological effects of the drug in combination with a second-generation tyrosine kinase inhibitor, pave the way for further clinical studies aimed at increasing the rate of DMR for a possible successful discontinuation. Commentary on: Irani et al. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. Br J Haematol 2023;202:1127-1136.
Substances chimiques
Protein Kinase Inhibitors
0
Pyrimidines
0
Interferon-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1087-1088Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385-1415.
Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia. 2013;27:803-812.
Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904-908.
Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214-220.
Nicolini FE, Etienne G, Huguet F, Guerci-Bresler A, Charbonnier A, Escoffre-Barbe M, et al. Treatment-free remissions in newly diagnosed CP CML patients treated with the combination of nilotinib+pegylated interferon alpha 2a versus nilotinib alone in the national phase III Petals trial. Blood. 2021;138(1):2553.
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al. Dasatinib plus peg-interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: results of a multicenter phase 2 study (DASA-PegIFN study). Br J Haematol. 2023;200(2):175-186.
Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Brummendorf TH, et al. Nilotinib vs nilotinib+peg-interferon alpha induction and nilotinib or peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. The Tiger trial. HemaSphere. 2023;7(s3):S157.
Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, et al. Efficacy of ropeginterferon alpha 2b in inducing treatment free remission in chronic myeloid leukemia-an international, randomized phase III trial (ENDURE, CML IX) of the German CML-study group. Blood. 2022;140(S1):1501-1503.
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
Irani YD, Hughes A, Kok CH, Clarson J, Yeung DT, Ross DM, et al. Immune modulation in chronic myeloid leukemia patients treated with nilotinib and interferon-alpha. Br J Haematol;202:1127-325.
Puzzolo MC, Breccia M, Mariglia P, Colafigli G, Pepe S, Scalzulli E, et al. Immunomodulatory effects of IFNa on T and NK cells in chronic myeloid leukemia patients in deep molecular response preparing for treatment discontinuation. J Clin Med. 2022;11(19):5594.